임상진료지침 개발 및 확산에 있어 이해상충문제
Conflicts of Interest in the Development and Dissemination of Clinical Practice Guidelines
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Clinical practice guidelines are systematically developed statements to assist practitioners and patients in making appropriate health care decisions in specific clinical circumstances. The potential influence of industry in the development or dissemination of clinical practice guidelines raises ethical concerns. A review of the development and dissemination of the Surviving Sepsis Campaign guidelines shows that the interaction between the pharmaceutical industry and academic societies can undermine clinical guidelines and harm the industry’s reputation. Thus, it is argued here that the process of developing and disseminating clinical practice guidelines should not be tainted by problems of corporate support and transparency. Furthermore, the process should identify and manage any conflicts of interest and ensure the patient-centeredness of the evaluation of emerging medical evidence.
Abstract
Clinical practice guidelines are systematically developed statements to assist practitioners and patients in making appropriate health care decisions in specific clinical circumstances. The potential influence of industry in the development or dissemination of clinical practice guidelines raises ethical concerns. A review of the development and dissemination of the Surviving Sepsis Campaign guidelines shows that the interaction between the pharmaceutical industry and academic societies can undermine clinical guidelines and harm the industry’s reputation. Thus, it is argued here that the process of developing and disseminating clinical practice guidelines should not be tainted by problems of corporate support and transparency. Furthermore, the process should identify and manage any conflicts of interest and ensure the patient-centeredness of the evaluation of emerging medical evidence.
참고문헌 (18)
- Abraham E, "Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death", N Engl J Med, 353, pp.1332~1341 (2005)
- Bernard GR, "Efficacy and safety of recombinant human activated protein C for severe sepsis", N Engl J Med, 344, pp.699~709 (2001)
- Billi JE, "Management of conflict of interest issues in the activities of the American Heart Association Emergency Cardiovascular Care Committee, 2000-2005", Circulation, 112, pp.IV204~IV205 (2005)
- Coyne DW, "Influence of industry on renal guideline development", Clin J Am Soc Nephrol, 2, pp.3~7 (2007)
- Dellinger RP, "Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock", Crit Care Med, 32, pp.858~873 (2004)
- Durbin CG Jr, "Is industry guiding the sepsis guidelines? A perspective", Crit Care Med, 35, pp.689~691 (2007)
- Eichacker PQ, "Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly", N Engl J Med, 355, pp.1640~1642 (2006)
- Levy MM, "The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis", Intensive Care Med, 36, pp.222~231 (2010)
- Nadel S, "Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial", Lancet, 369, pp.836~843 (2007)
- Poole D, "Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis", Lancet Infect Dis, 9, pp.67~72 (2009)
- Vincent JL, "Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment", Crit Care Med, 33, pp.2266~2277 (2005)
- 김남순, "임상진료지침 개발현황 및 정책과제", 보건복지포럼 (2004)
- 한서경, "근거중심보건의료" (2009), 고려의학